Patrick J. Grohar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick J. Grohar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Lee J. Helman
Authors' Affiliations: 1Monroe Carrell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Ingram Cancer Center, Nashville, Tennessee; 2Molecular Oncology Section, Pediatric Oncology Branch; 3Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and 4Istituto di Ricerche Farmacologiche “Mario Negri” -IRCCS, Milan, Italy
2 shared publicationsArnulfo Mendoza
Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
1 shared publicationChoh Yeung
Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
1 shared publicationLaure E. Segars
Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
1 shared publication- Maurizio D'Incalci
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
1 shared publication Yves Pommier
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
1 shared publication
Latest Publications
- Open Access
- 1 March 2014
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (5) , 1190-1203
Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
Purpose: The goal of this study is to optimize the activity of trabectedin for Ewing sarcoma by developing a molecularly targeted combination therapy. Experimental Design: We have recently shown that trabectedin interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. In this report, we build on this work to develop a trabectedin-based combination therapy with improved EWS-FLI1 suppression that also targets the drug-associated DNA damage to Ewing sarcoma cells. Results: We demonstrate by siRNA experiments that EWS-FLI1 drives the expression of the Werner syndrome protein (WRN) in Ewing sarcoma cells. Because WRN-deficient cells are known to be hypersensitive to camptothecins, we utilize trabectedin to block EWS-FLI1 activity, suppress WRN expression, and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. We show that trabectedin and SN38 are synergistic, demonstrate an increase in DNA double-strand breaks, an accumulation of cells in S-phase and a low picomolar IC50. In addition, SN38 cooperates with trabectedin to augment the suppression of EWS-FLI1 downstream targets, leading to an improved therapeutic index in vivo. These effects translate into the marked regression of two Ewing sarcoma xenografts at a fraction of the dose of camptothecin used in other xenograft studies. Conclusions: These results provide the basis and rationale for translating this drug combination to the clinic. In addition, the study highlights an approach that utilizes a targeted agent to interfere with an oncogenic transcription factor and then exploits the resulting changes in gene expression to develop a molecularly targeted combination therapy. Clin Cancer Res; 20(5); 1190–203. ©2013 AACR.
- 1 March 2014
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (5) , 1190-1203
Open AccessDual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
Purpose: The goal of this study is to optimize the activity of trabectedin for Ewing sarcoma by developing a molecularly targeted combination therapy. Experimental Design: We have recently shown that trabectedin interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. In this report, we build on this work to develop a trabectedin-based combination therapy with improved EWS-FLI1 suppression that also targets the drug-associated DNA damage to Ewing sarcoma cells. Results: We demonstrate by siRNA experiments that EWS-FLI1 drives the expression of the Werner syndrome protein (WRN) in Ewing sarcoma cells. Because WRN-deficient cells are known to be hypersensitive to camptothecins, we utilize trabectedin to block EWS-FLI1 activity, suppress WRN expression, and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. We show that trabectedin and SN38 are synergistic, demonstrate an increase in DNA double-strand breaks, an accumulation of cells in S-phase and a low picomolar IC50. In addition, SN38 cooperates with trabectedin to augment the suppression of EWS-FLI1 downstream targets, leading to an improved therapeutic index in vivo. These effects translate into the marked regression of two Ewing sarcoma xenografts at a fraction of the dose of camptothecin used in other xenograft studies. Conclusions: These results provide the basis and rationale for translating this drug combination to the clinic. In addition, the study highlights an approach that utilizes a targeted agent to interfere with an oncogenic transcription factor and then exploits the resulting changes in gene expression to develop a molecularly targeted combination therapy. Clin Cancer Res; 20(5); 1190–203. ©2013 AACR.
- 18 October 2012
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 137 (2) , 216-224
Prospects and challenges for the development of new therapies for Ewing sarcoma
- 18 October 2012
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 137 (2) , 216-224
Prospects and challenges for the development of new therapies for Ewing sarcoma